214 related articles for article (PubMed ID: 31273068)
1. Genetic polymorphisms in
Si W; Kang S; Sun H; Chen J; Cao S; Li Y
Int J Gynecol Cancer; 2019 Sep; 29(7):1148-1155. PubMed ID: 31273068
[TBL] [Abstract][Full Text] [Related]
2. Genetic variants and expression of the TIM-3 gene are associated with clinical prognosis in patients with epithelial ovarian cancer.
Wu JL; Zhao J; Zhang HB; Zuo WW; Li Y; Kang S
Gynecol Oncol; 2020 Oct; 159(1):270-276. PubMed ID: 32694063
[TBL] [Abstract][Full Text] [Related]
3. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
[TBL] [Abstract][Full Text] [Related]
4. The Association Between
Xing Z; Guo G; Pan X; Xu L; Guo C; An R
Genet Test Mol Biomarkers; 2019 Aug; 23(8):573-579. PubMed ID: 31373852
[No Abstract] [Full Text] [Related]
5. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
[TBL] [Abstract][Full Text] [Related]
6. Analysis of hMLH1 and hMSH2 expression in cisplatin-treated ovarian cancer patients.
Magnowska M; Surowiak P; Nowak-Markwitz E; Michalak M; Magnowski P; Rokita W; Kedzia H; Zabel M; Spaczyński M
Ginekol Pol; 2008 Dec; 79(12):826-34. PubMed ID: 19175039
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms in the Fas and FasL genes are associated with epithelial ovarian cancer risk and clinical outcomes.
Li Y; Hao YL; Kang S; Zhou RM; Wang N; Qi BL
Gynecol Oncol; 2013 Mar; 128(3):584-9. PubMed ID: 23234803
[TBL] [Abstract][Full Text] [Related]
8. nm23 gene polymorphisms are associated with survival of patients with epithelial ovarian cancer but not with susceptibility to disease.
Li Y; Kang S; Qin JJ; Wang N; Zhou RM; Sun HY
Gynecol Oncol; 2012 Sep; 126(3):455-9. PubMed ID: 22683585
[TBL] [Abstract][Full Text] [Related]
9. Association of Polymorphisms of Mismatch Repair Genes hMLHI and hMSH2 with Breast Cancer Susceptibility: A Meta-Analysis.
Zhang Q; Wang YN; Wu XY; Chen XD; Liu PQ; Li XS
Crit Rev Eukaryot Gene Expr; 2020; 30(3):253-264. PubMed ID: 32749112
[TBL] [Abstract][Full Text] [Related]
10. DNA repair gene associated with clinical outcome of epithelial ovarian cancer treated with platinum-based chemotherapy.
Kang S; Sun HY; Zhou RM; Wang N; Hu P; Li Y
Asian Pac J Cancer Prev; 2013; 14(2):941-6. PubMed ID: 23621265
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms of Selected DNA Repair Genes and Lung Cancer in Chromium Exposure.
Halasova E; Matakova T; Skerenova M; Krutakova M; Slovakova P; Dzian A; Javorkova S; Pec M; Kypusova K; Hamzik J
Adv Exp Med Biol; 2016; 911():17-22. PubMed ID: 26987333
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological and survival characteristic of mismatch repair status in ovarian clear cell carcinoma.
Zhu J; Ke G; Bi R; Wu X
J Surg Oncol; 2020 Sep; 122(3):538-546. PubMed ID: 32396667
[TBL] [Abstract][Full Text] [Related]
13. Expression and promoter methylation status of mismatch repair gene hMLH1 and hMSH2 in epithelial ovarian cancer.
Zhang H; Zhang S; Cui J; Zhang A; Shen L; Yu H
Aust N Z J Obstet Gynaecol; 2008 Oct; 48(5):505-9. PubMed ID: 19032668
[TBL] [Abstract][Full Text] [Related]
14. Association of Molecular Genetic Markers of TP53, MDM2, and CDKN1A Genes with Progression-Free Survival of Patients with Ovarian Cancer after Platinum-Based Chemotherapy.
Zavarykina TM; Tyulyandina AS; Khokhlova SV; Khabas GN; Asaturova AV; Nosova YA; Brenner PK; Kapralova MA; Atkarskaya MV; Khodyrev DS; Burdennyi AM; Loginov VI; Stenina MB; Sukhikh GT
Bull Exp Biol Med; 2020 Aug; 169(4):486-490. PubMed ID: 32910383
[TBL] [Abstract][Full Text] [Related]
15. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.
Moxley KM; Benbrook DM; Queimado L; Zuna RE; Thompson D; McCumber M; Premkumar P; Thavathiru E; Hines L; Moore KN
Gynecol Oncol; 2013 Aug; 130(2):377-82. PubMed ID: 23632208
[TBL] [Abstract][Full Text] [Related]
16. Intronic and promoter polymorphisms of hMLH1/hMSH2 and colorectal cancer risk in Heilongjiang Province of China.
Li G; Hu F; Yuan F; Fan J; Yu Z; Wu Z; Zhao X; Li Y; Li S; Rong J; Cui B; Dong X; Yuan H; Zhao Y
J Cancer Res Clin Oncol; 2015 Aug; 141(8):1393-404. PubMed ID: 25560462
[TBL] [Abstract][Full Text] [Related]
17. Rs3802278 in 3'-UTR of
Zeng F; Liu Y; Ouyang Q; Sun Z; Zhang K; Li X; Liu Y
J Chemother; 2021 Dec; 33(8):564-569. PubMed ID: 34029511
[TBL] [Abstract][Full Text] [Related]
18. VEGF gene polymorphisms and outcome of epithelial ovarian cancer patients.
Camerin GR; Brito AB; Vassallo J; Derchain SF; Lima CS
Future Oncol; 2017 Feb; 13(5):409-414. PubMed ID: 27780361
[TBL] [Abstract][Full Text] [Related]
19. [Relationship between hepatocellular carcinoma and the interaction between hMSH2 polymorphisms and environmental factors].
Tan S; Wang W; Liu S; Wei Q; Wei J; Wang Z; Yan M; Qiu X
Zhonghua Gan Zang Bing Za Zhi; 2014 Sep; 22(9):676-9. PubMed ID: 25369252
[TBL] [Abstract][Full Text] [Related]
20. Mismatch repair gene polymorphisms and association with lung cancer development.
Slováková P; Majerová L; Matáková T; Skereňová M; Kavcová E; Halašová E
Adv Exp Med Biol; 2015; 833():15-22. PubMed ID: 25252909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
